Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104987
Filing Date
2025-08-07
Accepted
2025-08-07 16:06:00
Documents
75
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ntla-20250630.htm   iXBRL 10-Q 2866214
2 EX-10.2 ntla-ex10_2.htm EX-10.2 52361
3 EX-10.3 ntla-ex10_3.htm EX-10.3 87623
4 EX-10.4 ntla-ex10_4.htm EX-10.4 65025
5 EX-10.5 ntla-ex10_5.htm EX-10.5 59786
6 EX-10.6 ntla-ex10_6.htm EX-10.6 50070
7 EX-31.1 ntla-ex31_1.htm EX-31.1 14887
8 EX-31.2 ntla-ex31_2.htm EX-31.2 14907
9 EX-32.1 ntla-ex32_1.htm EX-32.1 9747
  Complete submission text file 0000950170-25-104987.txt   10612319

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20250630.xsd EX-101.SCH 1243724
78 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20250630_htm.xml XML 1947213
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 251193913
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)